UC Davis

UC Davis Previously Published Works

Title

Feline conjunctival microbiota in a shelter: effects of time, upper respiratory disease and famciclovir administration.

Permalink

<https://escholarship.org/uc/item/1615x46n>

Journal

Journal of feline medicine and surgery, 23(4)

ISSN

1098-612X

Authors

Lucyshyn, Danica R
Maggs, David J
Cooper, Ann E
et al.

Publication Date

2021-04-01

DOI

10.1177/1098612x20949038

Peer reviewed

Feline conjunctival microbiota in a shelter: effects of time, upper respiratory disease and famciclovir administration

Journal of Feline Medicine and Surgery
1–15

© The Author(s) 2020

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/1098612X20949038

journals.sagepub.com/home/jfm

This paper was handled and processed
by the American Editorial Office (AAFP)
for publication in *JFMS*

Danica R Lucyshyn¹, David J Maggs¹, Ann E Cooper²,
Joyce D Rousseau³ and J Scott Weese³

Abstract

Objectives The aim of this study was to evaluate changes in the conjunctival microbiota of shelter-housed cats with time, upper respiratory disease (URD) and famciclovir administration.

Methods Cats were assigned to treatment groups on shelter entry. Healthy cats or cats with URD received ~30mg/kg or ~90mg/kg of famciclovir or placebo PO q12h for 7 days, or were untreated. Swabs were collected from ventral conjunctival fornices prior to (day 1) and immediately after (day 8) the treatment period. Microbiota analysis was conducted on 124 randomly selected swabs from healthy (56 swabs) or URD-affected (68 swabs) cats. Following DNA extraction and amplification of the V4 region of the 16S rRNA gene, sequences were assembled into operational taxonomic units (OTUs). Over-represented OTUs (as determined by linear discriminate analysis effect size), alpha and beta diversity, and median relative abundance of known feline ocular surface pathogens were assessed for the entire population and in 10 clinically relevant subpopulations of cats.

Results Bacteria from 33 phyla and 70 genera were identified. Considering all cats, median relative abundance of *Mycoplasma* increased from day 1 to day 8, while Proteobacteria decreased. Community membership and structure (beta diversity) differed between days 1 and 8 for all famciclovir-treated cats (regardless of health status or dose) and healthy or URD-affected cats (regardless of famciclovir dose). Differences in taxonomic diversity within a sample (alpha diversity) between day 1 and day 8 were not detected in any subpopulations.

Conclusions and relevance Within 1 week of shelter entry, there were significant changes in community structure and membership of the feline conjunctival microbiota, with a shift towards over-representation of feline ocular surface pathogens. Although famciclovir may impact beta diversity of the feline conjunctival microbiota, absence of change in alpha diversity suggests minimal shift in individual cats.

Keywords: Antiviral drugs; ocular disease; microbiome; population health; metagenomics

Accepted: 20 July 2020

Introduction

The community of living microorganisms in a particular environment, including its inhabitant bacteria, viruses, fungi and protozoa, is termed the microbiota.^{1–4} By contrast, the microbiome describes all genetic material within the microbiota.^{4,5} Initial investigation of the microbiota and microbiome was limited to culture-based and similar techniques. The advent of metagenomic techniques, such as 16S ribosomal RNA (16S rRNA) gene sequencing, as well as bioinformatics systems, have allowed broader and more detailed investigation of the microbiome and microbiota, and their associations with various host factors and pharmacologic interventions.^{2,3,5–9}

¹Department of Surgical and Radiological Sciences, University of California–Davis, Davis, CA, USA

²Veterinary Medical Teaching Hospital, University of California–Davis, Davis, CA, USA

³Department of Pathobiology, University of Guelph, Guelph, ON, Canada

Corresponding author:

David J Maggs BVSc (Hons), DACVO, Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, 2112 Tupper Hall, Davis, CA 95616, USA
Email: djmaggs@ucdavis.edu

Evaluation of the bacterial microbiota can involve various approaches, including comparison of specific members (eg, different phyla and genera), alpha diversity indices (ecological indicators of the bacterial community in a sample) and assessment of beta diversity (evaluation of differences in overall bacterial communities between groups). Additional approaches can be used to provide different insights, such as the use of linear discriminate analysis effect size (LEfSe) to identify operational taxonomic units (OTUs) that are differentially abundant in species groups. Microbiota analysis frequently begins following assembly of sequences with greater than 97% nucleotide identity into groups called OTUs.^{3,10} Alpha diversity metrics indicate the taxonomic diversity (inverse Simpson's index), evenness (Shannon's evenness index) and richness (number of species observed [observed species richness: SOBS] and Chao1 index).^{3,10–12} Beta diversity metrics include measurements of microbial community membership (number of shared genera; Jaccard's index) and structure (number of shared genera and their relative abundances; Yue and Clayton index) between samples.¹⁰ A wide range of methods can be used to compare statistically the composition of microbiota communities, such as analysis of molecular variance (AMOVA) and unweighted UniFrac. Briefly, UniFrac measures differences in branch lengths between taxa in a phylogenetic tree,¹³ and AMOVA measures differences between the genetic diversity of multiple communities and their pooled genetic diversity.¹⁴ While there are no standard approaches to microbiota assessment, a combination of assessment of taxonomic differences, alpha diversity and beta diversity allow for detailed assessment of specific and broad aspects of the microbiota.

Host-microbiome interactions are complex, and whether changes in the host precede changes in its microbiome, or vice versa, is largely unknown; however, the relationship is undoubtedly important. For example, studies in humans have proposed a connection between the microbiome and cancer, obesity, asthma, atherosclerosis and diabetes.^{2,15} The ocular microbiome has also received attention, with blepharitis, meibomian gland disorders, chronic inflammation, ocular rosacea,¹⁶ sleep duration¹⁷ and contact lens use^{16,18} each associated with alterations in composition of the human ocular microbiome.

The feline microbiota has received some research attention. In clinically normal cats, the conjunctival microbiome (lower conjunctival sac/fornix, eyelid margins, and palpebral conjunctiva of third eyelid) has been examined using culture-based^{19–21} and metagenomic/bioinformatics²² techniques. Changes to the nasal microbiome have been identified in cats of different ages and those living in different environments,⁵ and as a function of season.¹⁹ Likewise, the microbiome of cats affected by feline immunodeficiency virus (FIV),²² acute and chronic gastrointestinal disease,²³ and conjunctivitis²⁰ have all

been demonstrated as quantitatively or qualitatively different than those of their healthy counterparts. However, to our knowledge there are no published genomic studies assessing the microbiota of cats housed within a shelter environment, or the effect of upper respiratory disease (URD) or the administration of antiviral medications. Considering the ubiquitous nature of URD infection in shelter-housed cats,^{24,25} the impact of host and environmental factors on the host microbiome and development of feline URD, alterations in the microbiome of cats with conjunctivitis,²⁰ and the effects of time in a shelter on shedding of viral and bacterial pathogens associated with feline URD,^{26,27} we were interested in assessing the conjunctival microbiota of cats in a shelter environment. The objectives of the present study were to evaluate the conjunctival microbiota of clinically healthy and URD-affected, shelter-housed cats for changes associated with time, URD status and treatment effect of two doses of the antiviral agent famciclovir.

Materials and methods

Cats and treatment groups

This study used conjunctival swabs collected as part of a project assessing the prophylactic and therapeutic effects of famciclovir on infectious URD in shelter-housed cats.²⁸ All samples were collected between March and November 2016 from cats housed in a county animal shelter in Northern California. All cats were held for a legally mandated 72h period after arriving at the shelter, during which time they underwent behavioral testing, and intact cats were neutered. Cats were considered for study enrollment within 48h of being listed for adoption. The study was approved by the Institutional Animal Care and Use Committee of the University of California–Davis (IACUC #18929) and designed in accordance with the Association for Research in Vision and Ophthalmology statement for the ethical use of animals in ophthalmic research.

Inclusion criteria were body weight ≥ 1 kg, body condition score $\geq 3/9$, negative serum feline leukemia virus antigen and FIV antibody test results (SNAP Combo FeLV Ag-FIV Antibody test; IDEXX) and aged ≥ 3 months old (as estimated based on dental examination). Any cat that lost $>15\%$ of its entry body weight was excluded from the study.²⁸ Cats meeting all the inclusion criteria were graded by masked observers for clinical signs of URD according to an established semi-quantitative scoring system for clinical evidence of FHV-1-associated disease.²⁹ All ocular (conjunctivitis, blepharospasm and ocular discharge) and non-ocular (sneezing and nasal discharge) scores were summed to determine the total clinical disease score, which ranged from 0 to 24. Cats were then randomized to one of seven treatment groups by a single researcher uninvolved in subsequent clinical assessments. Randomization was performed such that

all groups in both arms had approximately equivalent sex and age distribution. Cats without evidence of URD (ie, clinical disease score = 0) received either no treatment or ~30 mg/kg or ~90 mg/kg PO q12h for 7 days famciclovir. Cats with evidence of URD (ie, clinical disease score ≥ 1) received either no treatment, or lactose (placebo), or ~30 or ~90 mg/kg of famciclovir PO q12h for 7 days.²⁸

Swab collection and microbiota analysis

On day 1 (study entry) and day 8 (cessation of famciclovir/placebo administration), cats in all seven treatment groups received one drop of 0.5% proparacaine (Akorn) in each eye, and a dry polyester swab (Fisher Scientific) was rolled vigorously in the ventral conjunctival fornix of both eyes. All swabs were immediately placed into cryovials, stored on ice for 1–3 h, and then at -80°C until genomic analysis. Samples were collected for microbiota assessment from 158 cats from which a convenience subset of 151 swabs from 99 cats was selected by laboratory personnel masked to all information about sample source.

The DNA was extracted from swabs using the Qiagen DNeasy Power Soil Kit with an extra step of heating at 70°C before continuing with step 5. The DNA was eluted into a 30 ml volume of elution buffer. Quantification of DNA was performed using a NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies). The V4 region of the 16S rRNA gene was amplified using the modified primers 515-F/806-R.^{30,31} Each 25 μl mix consisted of 12.5 μl of KAPA2G Fast HotStart ReadyMix (KAPA Biosystems), 0.5 μl (10 pM/ μl) of each of the primers, 2 μl of DNA template and 9.5 μl of PCR-grade water. The following PCR conditions were used: 3 mins at 94°C for denaturing, followed by 30 cycles of 45 s at 94°C , 60 s at 52°C and 60 s at 72°C , with a final period of 10 mins at 72°C . The PCR products were purified with Mag Bind RXNPure Plus beads (Omega Bio-tech). A second PCR reaction was used for attachment of Illumina adapter primers (N716-N729 and S513-S522). A final mix containing 5.0 μl of DNA template, 4.0 μl of primers (2.5 pM/ μl) and 12.0 μl of PCR-grade water underwent cycling for 3 mins at 94°C followed by eight cycles of 30 s at 94°C , 30 s at 55°C and 30 s at 72°C , plus a final period of 10 mins at 72°C . After purification (Mag Bind RXNPure Plus; Omega Bio-tech), sequencing was performed using Illumina MiSeq and 2×250 chemistry.

Forward and reverse sequence reads were assembled and subjected to a series of quality control steps using Mothur 1.42.3 to remove primers, sequences that were of abnormal size or contained ambiguous base calls, sequences not consistent with the V4 regions and chimeras.³² Sequences were assembled into OTUs using a de novo (open OTU) picking approach with a 3% dissimilarity cut-off. Individual sequences and OTUs were classified using the Ribosomal Database Project Classifier.³³

Data analysis

Prior to analysis, data were assessed using the Shapiro–Wilk test of normality. Because a large proportion of data sets were non-normally distributed, all data were converted to ranks using commercially available software (SigmaPlot 14.0; Systat Software). Sequence data were unmasked and linked to the individual cat and swab from which they were collected. Data were excluded from any cat that developed illness requiring medical intervention. This included development of URD and/or ocular disease treated with antibiotics administered orally and/or topically (15 cats), diarrhea treated with sulfadimethoxine (one cat), and/or gastrointestinal parasitism treated with fenbendazole (one cat). Additionally, one cat developed liver failure and was humanely euthanized. According to these criteria, 27 samples from 18 cats were excluded from subsequent analyses.

To evaluate for microbial changes within the entire study population, data from swabs collected on day 1 were compared with those collected on day 8 in all cats ($n = 81$) collectively. To assess for other clinically relevant changes, sequence data were re-grouped to allow more granular comparisons among 10 subpopulations: healthy untreated cats; URD-affected untreated cats; URD-affected placebo-treated cats; URD-affected and healthy famciclovir-treated cats; URD-affected famciclovir-treated cats; URD-affected cats receiving 30 mg/kg famciclovir; URD-affected cats receiving 90 mg/kg famciclovir; healthy famciclovir-treated cats; healthy cats receiving 30 mg/kg famciclovir; and healthy cats receiving 90 mg/kg famciclovir.

Alpha diversity was analyzed by comparing diversity (inverse Simpson index), evenness (Shannon's evenness index) and richness (number of species observed and Chao1 index) among subpopulations. Differences in alpha diversity and median relative abundance between days 1 and 8 were assessed using the Kruskal–Wallis one-way ANOVA on ranks with Dunn's all multiple comparison procedures for difference in ranks. Differences in alpha diversity and median relative abundance between doses of famciclovir were each assessed using the Mann–Whitney rank sum test with a Yates continuity correction. Beta diversity was analyzed by UniFrac analysis of Jaccard and Yue and Clayton indices so as to compare microbial community membership (unweighted) and structure (weighted), respectively, and via AMOVA.

To ensure that specific pathogens were individually assessed, median relative abundance of selected genera or phyla containing known feline ocular surface pathogens (*Mycoplasma*, *Streptococcus*, *Pseudomonas*, Chlamydiae and Proteobacteria) were compared. The LEfSe method was used to identify differentially abundant OTUs for each time point in each population. An OTU with a linear discriminant analysis >4 was considered to be over-represented. For assessment of alpha and beta diversity, sequence numbers were normalized through random selection of

6480 sequences per sample. Beta diversity was also analyzed using non-subsampled data; values obtained were very similar to those for the subsampled data; therefore, no further analysis of non-subsampled data was performed.

All analyses of alpha diversity and median relative abundance were performed using commercial software (SigmaPlot 14.0; Systat Software), and *P* values were adjusted for false discovery rate using the Benjamini–Hochberg technique. All beta diversity analyses were performed using open access software (Mothur v1.42.3).³² For all statistical analyses, a *P* value of ≤ 0.05 was considered significant.

Results

Following exclusion of 27 samples from 18 cats that received medications other than famciclovir during the study period, 124 conjunctival swab samples that passed all quality control steps were assessed. These comprised 56 swabs from healthy cats and 68 swabs from URD-affected cats (Figure 1) from which bacteria belonging to 33 phyla and 70 genera were identified.

Effect of time in the shelter on feline ocular surface pathogens and the conjunctival microbiota of the entire study population

Considering the entire population (irrespective of cat health status and treatment group), *Mycoplasma*, *Streptococcus* and *Pseudomonas* were isolated from all 124 samples, and their median relative abundance was 0.0117, 0.0268 and 0.0021, respectively (Figure 2). Proteobacteria

were detected in all 124 samples analyzed and Chlamydiae in 48/124 (39%). Median relative abundance for Proteobacteria and Chlamydiae was 0.1596 and 0, respectively (Figure 3). Of the five ocular surface pathogens analyzed, significant differences in relative abundance between days 1 and 8 were detected only for *Mycoplasma* and Proteobacteria. For all comparisons of clinical interest (Table 1), median relative abundance of *Mycoplasma* tended to increase from day 1 to day 8, and did so significantly in three populations assessed – all 81 cats when considered as a whole, those receiving famciclovir regardless of health status or famciclovir dose, and URD-affected untreated cats. By contrast, median relative abundance for Proteobacteria decreased significantly over the study week only when the entire study population was considered as a whole (Table 1).

LEfSe analysis revealed that *Escherichia/Shigella* was over-represented on day 1 and *Clostridium* cluster XI, *Mycoplasma*, *Staphylococcus* and *Streptococcus* were over-represented on day 8 (Table 2). Both community membership and community structure differed significantly between days 1 and 8, whether assessed by AMOVA or UniFrac (Figures 4 and 5; Table 3). However, no significant differences in observed or estimated richness, diversity or evenness were identified among all cats between days 1 and 8 (Figures 6 and 7).

Effect of time in the shelter on the conjunctival microbiota of untreated cats

In URD-affected untreated cats, LEfSe analysis indicated that *Escherichia/Shigella* was the only OTU over-represented

Figure 1 Number of conjunctival swabs (in parentheses) undergoing microbiota analysis from 81 shelter-housed cats with or without clinical evidence of upper respiratory disease (URD) that were untreated or received orally administered famciclovir at one of two doses or placebo (lactose) q12h for 7 days. Swabs were collected prior to (day 1) and immediately after (day 8) the 7-day treatment period

Figure 2 Distribution of 11/70 bacterial genera isolated from 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease (URD). Cats were untreated or received orally administered famciclovir at 30mg/kg or 90mg/kg or placebo (lactose) q12h for 7 days. Genera selected for graphic representation were those over-represented at any time for any population and those that contained ocular surface pathogens. Swabs were collected prior to (day 1; left bar of each pair on chart) and immediately after (day 8; right bar of each pair on chart) the 7-day study period. Data are presented for all swabs combined (ALL), ie, day 1 and day 8 samples from the entire study population, and for the 11 clinically relevant populations described in Figure 1: (A) entire population; (B) healthy untreated cats; (C) URD-affected untreated cats; (D) URD-affected placebo-treated cats; (E) healthy and URD-affected famciclovir-treated (30mg/kg or 90mg/kg) cats; (F) healthy famciclovir-treated (30mg/kg or 90mg/kg) cats; (G) URD-affected famciclovir-treated (30mg/kg or 90mg/kg) cats; (H) URD-affected famciclovir-treated (30mg/kg) cats; (I) healthy famciclovir-treated (30mg/kg) cats; (J) URD-affected famciclovir-treated (90mg/kg) cats; and (K) healthy famciclovir-treated (90mg/kg) cats

on day 1, whereas *Mycoplasma* and *Streptococcus* were over-represented on day 8 (Table 2). There was a significant increase in the median relative abundance of *Mycoplasma* between day 1 and day 8 (Table 1). The only significant change in beta diversity was in microbial community structure between day 1 and day 8 as measured by AMOVA (Table 3). There were no significant differences between days 1 and 8 in alpha diversity in this population (Figures 6 and 7).

By comparison, in healthy untreated cats, over-represented OTUs at day 1 were *Escherichia/Shigella* and *Bacteroides*, and at day 8 were *Clostridium* cluster XI and *Staphylococcus* (Table 2). No significant differences in median relative abundance were apparent between days 1 and 8 for any of the common ocular surface pathogens analyzed in this population (Table 1). There were significant differences between days 1 and 8 in microbial community structure (as measured by unweighted UniFrac and AMOVA) and community membership (as compared by unweighted UniFrac; Table 3). There were no significant differences in the alpha diversity measures of observed or estimated richness, diversity or evenness (Figures 6 and 7). Additionally, there were no significant

differences in community membership or structure between URD-affected untreated and healthy untreated cats at either day 1 or day 8 (Table 4).

Effect of placebo treatment on the conjunctival microbiota of URD-affected cats

The predominant OTUs in URD-affected placebo-treated cats, based on LEfSe analysis, were *Bacteroides*, *Fusobacterium*, *Escherichia/Shigella* and *Gallibacterium* at day 1, and *Clostridium* cluster XI at day 8 (Table 2). No significant differences in median relative abundance of ocular surface pathogens were detected between days 1 and 8 in this population (Table 1). Considering just URD-affected placebo-treated cats, significant differences between days 1 and 8 were detected only in community structure as assessed by AMOVA (Table 3). No significant differences were detected over time in community structure by UniFrac, community membership or alpha diversity. Additionally, on neither day 1 nor day 8 was a significant difference detected in community membership or structure between URD-affected cats that were untreated and those that were placebo-treated (Table 4).

Figure 3 Distribution of 6/33 bacterial phyla isolated from 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease (URD). Cats were untreated or received orally administered famciclovir at 30 mg/kg or 90 mg/kg or placebo (lactose) q12h for 7 days. Phyla selected for graphic representation were those with a median relative abundance >0.046 and those that contained ocular surface pathogens. Swabs were collected prior to (day 1; left bar of each pair on chart) and immediately after (day 8; right bar of each pair on chart) the 7-day study period. Data are presented for all swabs combined (ALL), ie, day 1 and day 8 samples from the entire study population, and for the 11 clinically relevant populations described in Figure 1: (A) entire population; (B) healthy untreated cats; (C) URD-affected untreated cats; (D) URD-affected placebo-treated cats; (E) healthy and URD-affected famciclovir-treated (30 mg/kg or 90 mg/kg) cats; (F) healthy famciclovir-treated (30 mg/kg or 90 mg/kg) cats; (G) URD-affected famciclovir-treated (30 mg/kg or 90 mg/kg) cats; (H) URD-affected famciclovir-treated (30 mg/kg) cats; (I) healthy famciclovir-treated (30 mg/kg) cats; (J) URD-affected famciclovir-treated (90 mg/kg) cats; and (K) healthy famciclovir-treated (90 mg/kg) cats

Table 1 Median relative abundance of *Mycoplasma* and Proteobacteria from 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease (URD) that were untreated or received orally administered famciclovir at one of two doses or placebo (lactose) q12h for 7 days

Subpopulation assessed	Median relative abundance (n = number of swabs)					
	<i>Mycoplasma</i>			Proteobacteria		
	Day 1	Day 8	<i>P</i> value (BH)	Day 1	Day 8	<i>P</i> value (BH)
All cats (regardless of health status or treatment)	0.0053 (53)	0.0219 (80)	0.011	0.1956 (50)	0.1453 (75)	0.011
Healthy, untreated	0.0032 (7)	0.0085 (16)	0.097	0.2203 (7)	0.1549 (15)	0.299
URD-affected, untreated	0.0047 (9)	0.0344 (11)	0.026	0.1820 (9)	0.1860 (11)	1.000
URD-affected, placebo-treated	0.0010 (8)	0.1287 (8)	0.097	0.2097 (7)	0.0963 (7)	0.697
Healthy and URD-affected, famciclovir-treated (30 mg/kg and 90 mg/kg)	0.0069 (29)	0.0168 (45)	0.026	0.1841 (27)	0.1293 (42)	0.072
Healthy, famciclovir-treated (30 mg/kg and 90 mg/kg)	0.0048 (16)	0.0128 (23)	0.097	0.2457 (14)	0.1339 (20)	0.072
URD-affected, famciclovir-treated (30 mg/kg and 90 mg/kg)	0.0073 (13)	0.0394 (22)	0.097	0.1537 (13)	0.1255 (22)	0.698
URD-affected, famciclovir-treated (30 mg/kg)	0.0064 (8)	0.0605 (13)	0.097	0.1555 (8)	0.1190 (13)	0.698
URD-affected, famciclovir-treated (90 mg/kg)	0.0146 (5)	0.0215 (9)	0.639	0.1428 (5)	0.2124 (9)	1.000
Healthy, famciclovir-treated (30 mg/kg)	0.0024 (6)	0.0214 (10)	0.097	0.2034 (6)	0.1242 (10)	0.698
Healthy, famciclovir-treated (90 mg/kg)	0.0083 (10)	0.0128 (13)	0.644	0.2693 (8)	0.1388 (10)	0.072

Swabs were collected prior to (day 1) and immediately after (day 8) the 7-day study period. Data are compared across the entire population and for all clinically relevant subpopulations. The values in bold are significant at $P \leq 0.05$. No significant differences were detected for the remaining three ocular surface pathogens (*Chlamydiae*, *Streptococcus* and *Pseudomonas*)

BH = Benjamini-Hochberg

Table 2 Over-represented operational taxonomic units (OTUs) of bacterial genera from 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease (URD)

Over-represented operational taxonomic units												
	Day	A	B	C	D	E	F	G	H	I	J	K
<i>Bacteroides</i>	1		4.32		4.63		4.20		4.19			
	8											4.25
<i>Clostridium</i> cluster XI	1											
	8	4.68	4.60		4.70	4.45	4.68	4.61	4.76	4.53		4.73
<i>Escherichia/Shigella</i>	1	4.49	4.52	4.33	4.58			4.87				
	8											
<i>Fusobacterium</i>	1				4.61						4.36	
	8											
<i>Gallibacterium</i>	1				4.12					4.18		
	8											
<i>Meiothermus</i>	1					4.22						
	8											
<i>Mycoplasma</i>	1											
	8	4.48		4.59		4.51	4.51		4.79			
<i>Pasteurella</i>	1									4.06		
	8											
<i>Staphylococcus</i>	1											
	8	4.39	4.54			4.45	4.36	4.29	4.43	4.73		4.16
<i>Streptococcus</i>	1											
	8	4.01		4.31								

Swabs were collected prior to (day 1) and immediately after (day 8) a 7-day study period during which cats were untreated or received orally administered famciclovir at 30 mg/kg or 90 mg/kg or placebo (lactose) q12h. For analysis, cats were considered within the following 11 subgroups: (A) entire population; (B) healthy untreated cats; (C) URD-affected untreated cats; (D) URD-affected placebo-treated cats; (E) healthy and URD-affected famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (F) healthy famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (G) URD-affected famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (H) URD-affected famciclovir-treated (30 mg/kg) cats; (I) healthy famciclovir-treated (30 mg/kg) cats; (J) URD-affected famciclovir-treated (90 mg/kg) cats; and (K) healthy famciclovir-treated (90 mg/kg) cats. OTUs were defined as those with linear discriminate analysis (LDA) values >4.00 based on LDA effect size (LEfSe) analysis

Effect of famciclovir administration on the conjunctival microbiota of healthy and URD-affected cats

The over-represented OTUs for all famciclovir-treated cats considered collectively (regardless of health status or famciclovir dose) were *Meiothermus* at day 1, and *Mycoplasma*, *Staphylococcus* and *Clostridium* cluster XI at day 8 (Table 2). There was also a significant increase in median relative abundance of *Mycoplasma* from day 1 to day 8 (Table 1). Median relative abundance did not differ significantly between these two time points for any other ocular surface pathogens. No significant differences were detected between day 1 and day 8 in the beta diversity parameters of community membership and structure (as analyzed by UniFrac and AMOVA; Table 3) or for any measures of alpha diversity in this population (Figures 6 and 7).

LEfSe analysis indicated that the over-represented OTUs for cats that were healthy at shelter entry and treated with either dose of famciclovir were *Bacteroides* at day 1 and *Clostridium* cluster XI, *Mycoplasma* and

Staphylococcus at day 8 (Table 2). There was a significant increase in median relative abundance of *Mycoplasma* between days 1 and 8 (Table 1). There were also significant differences in community structure and membership by AMOVA and UniFrac between day 1 and day 8 for this population (Table 3). No significant changes in measures of alpha diversity, evenness, or richness between days 1 and 8 were apparent (Figures 6 and 7).

The over-represented OTUs for URD-affected cats treated with either dose of famciclovir were *Escherichia/Shigella* at day 1 and *Clostridium* cluster XI and *Staphylococcus* at day 8 (Table 2). There were no significant differences between day 1 and day 8 in the median relative abundance (Table 1) of the ocular surface pathogens assessed for this population. There were significant differences in community structure (as assessed by AMOVA and UniFrac), and in community membership (as assessed by UniFrac) between day 1 and day 8 in this population (Table 3). No significant difference was detected between day 1 and 8 in the alpha diversity of any of the ocular surface pathogens assessed (Figures 6 and 7).

Figure 4 Beta diversity of the conjunctival microbiota analyzed using Jaccard's index (community membership) performed on 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease. Each point represents the microbial community of a conjunctival swab collected prior to (day 1; blue dots and ellipse) or immediately after (day 8; red dots and ellipse) a 7-day study period during which they were untreated or received orally administered famciclovir at 30mg/kg or 90mg/kg, or placebo (lactose) q12h. Data for each day represent the entire study population irrespective of treatment group or disease status. Non-metric multidimensional scaling (NMDS) Axis 1 and Axis 2 represent the axes of the two-dimensional ordination space. Ellipses represent the 95% confidence intervals at each time point

Considering only URD-affected cats receiving 30mg/kg famciclovir, the over-represented OTUs were *Bacteroides* at day 1 and *Mycoplasma*, *Clostridium* cluster XI and *Staphylococcus* at day 8 (Table 2). There were no significant differences in the median relative abundance of ocular surface pathogens between day 1 and 8 for this population (Table 1). Regardless of whether the data were analyzed by AMOVA or by UniFrac, no significant differences in community structure or membership were detected between days 1 and 8 (Table 3), or in any measures of alpha diversity (Figures 6 and 7).

In healthy cats treated with 30mg/kg famciclovir, the over-represented OTUs were *Gallibacterium* and *Pasteurella* at day 1 and *Staphylococcus* and *Clostridium* cluster XI at day 8 (Table 2). No significant differences were present in the median relative abundance of ocular surface pathogens between days 1 and 8 in this population (Table 1). Community membership only differed significantly between days 1 and 8 by AMOVA in this population. Community structure was not significantly different between days 1 and 8 (Table 3). There were also no significant differences in alpha diversity between day 1 and day 8 (Figures 6 and 7).

Figure 5 Beta diversity of the conjunctival microbiota analyzed using Yue and Clayton's index (community structure) performed on 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease. Each point represents the microbial community of a conjunctival swab collected prior to (day 1; blue dots and ellipse) or immediately after (day 8; red dots and ellipse) a 7-day study period during which they were untreated or received orally administered famciclovir at 30mg/kg or 90mg/kg, or placebo (lactose) q12h. Data for each day represent the entire study population irrespective of treatment group or disease status. Non-metric multidimensional scaling (NMDS) Axis 1 and Axis 2 represent the axes of the two-dimensional ordination space. Ellipses represent the 95% confidence intervals at each time point

For URD-affected cats treated with 90mg/kg famciclovir, the only over-represented OTU was *Fusobacterium* at day 1 (Table 2). There were no significant differences detected between day 1 and day 8 in the median relative abundance of any ocular surface pathogens (Table 1). No significant differences in beta diversity, community structure or community membership were observed between days 1 and 8 in this population (Table 3).

Considering only healthy cats receiving 90mg/kg famciclovir, there were no over-represented OTUs at day 1; however, the over-represented OTUs in this population at day 8 were *Bacteroides*, *Staphylococcus* and *Clostridium* cluster XI (Table 2). There were no significant differences between days 1 and 8 in median relative abundance of ocular surface pathogens (Table 1). Significant differences were apparent in community membership between days 1 and 8 as measured by AMOVA and UniFrac (Table 3). There were no significant changes in community structure between these time points.

Alpha diversity did not significantly differ between day 1 and day 8 for either the healthy or URD-affected population (Figures 6 and 7). Additionally, there were no significant changes in community structure or membership

Table 3 Community membership (Jaccard index) and structure (Yue and Clayton index) by analysis of molecular variance (AMOVA) and UniFrac from 124 conjunctival swabs collected from 81 shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease (URD) that were untreated or received orally administered famciclovir at one of two doses or placebo (lactose) q12h for 7 days

Beta diversity (community membership and structure) between days 1 and 8			
Subpopulation assessed	Analysis	Jaccard (membership) P value	Yue/Clayton (structure) P value
All cats (regardless of health status or treatment)	AMOVA	<0.001	<0.001
	UniFrac	<0.001	<0.001
Healthy, untreated	AMOVA	0.081	0.009
	UniFrac	0.011	0.028
URD-affected, untreated	AMOVA	0.220	0.033
	UniFrac	0.097	0.162
URD-affected, placebo-treated	AMOVA	0.302	0.025
	UniFrac	0.433	0.143
Healthy and URD-affected, famciclovir-treated (30mg/kg and 90mg/kg)	AMOVA	0.001	<0.001
	UniFrac	<0.001	<0.001
Healthy, famciclovir-treated (30mg/kg and 90mg/kg)	AMOVA	0.002	0.003
	UniFrac	0.003	0.020
URD-affected, famciclovir-treated (30mg/kg and 90mg/kg)	AMOVA	0.095	0.016
	UniFrac	0.002	0.030
URD-affected, famciclovir-treated (30mg/kg)	AMOVA	0.295	0.126
	UniFrac	0.081	0.084
URD-affected, famciclovir-treated (90mg/kg)	AMOVA	0.312	0.339
	UniFrac	0.130	0.316
Healthy, famciclovir-treated (30mg/kg)	AMOVA	0.050	0.112
	UniFrac	0.238	0.358
Healthy, famciclovir-treated (90mg/kg)	AMOVA	0.042	0.082
	UniFrac	0.050	0.314

Swabs were collected prior to (day 1) and immediately after (day 8) the 7-day study period. Data are compared across the entire population and for all clinically relevant subpopulations. The values in bold are significant at $P \leq 0.05$

when comparing healthy and URD-affected cats treated with 90mg/kg famciclovir at either day 1 or day 8 (Table 4).

To evaluate the effect of famciclovir dose, conjunctival microbiota from swabs collected on day 1 were compared between healthy cats treated with 30mg/kg famciclovir and those treated with 90mg/kg famciclovir, and between URD-affected cats treated with 30mg/kg famciclovir and those treated with 90mg/kg famciclovir. No significant differences in the alpha diversity or beta diversity were detected (Table 5; Figures 6 and 7), and no difference in median relative abundance of the five ocular surface pathogens was detected for any population (Table 6).

Discussion

In the present study, we were consistently able to detect bacteria from conjunctival swabs collected from various populations of shelter-housed cats at study entry and 1 week later. This resulted in a large and complex data set, which permitted assessment of alpha diversity, beta diversity and median relative abundance of the conjunctival microbiota as a whole and of phyla or genera

containing $\geq 1/5$ selected feline ocular surface pathogens. The methodology for best interpreting these results remains under development; however, using currently accepted techniques we were able to assess potential effects of time in a shelter environment, famciclovir administration and dose, and URD status on the feline conjunctival microbiota generally, as well as *Mycoplasma*, *Streptococcus* and *Pseudomonas*, Chlamydiae, and Proteobacteria.

Our data suggest that within 1 week in a shelter environment there were changes in community structure and membership of the conjunctival microbiota, with a shift towards over-representation of some ocular surface pathogens. At shelter entry, only *Escherichia/Shigella* was over-represented; these two phyla are difficult to differentiate by 16S rRNA gene analysis and are therefore reported combined. By day 8, *Mycoplasma*, *Clostridium* cluster XI, *Staphylococcus* and *Streptococcus* were all over-represented. Simultaneously, changes were also identified in beta diversity measures which were, at least in part, related to alterations in the median relative

Figure 6 Alpha diversity of the conjunctival microbiota assessed using 50 swabs collected at shelter entry (day 1) from 50 cats with ($n = 29$) or without ($n = 21$) clinical evidence of upper respiratory disease (URD). Cats subsequently underwent a 7-day study period during which they were untreated or received orally administered famciclovir at 30 mg/kg or 90 mg/kg or placebo (lactose) q12h, and alpha diversity was assessed again on day 8 (see Figure 7). For data analysis, cats were considered within 11 populations as described in Figure 1: (A) entire population; (B) healthy untreated cats; (C) URD-affected untreated cats; (D) URD-affected placebo-treated cats; (E) healthy and URD-affected famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (F) healthy famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (G) URD-affected famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (H) URD-affected famciclovir-treated (30 mg/kg) cats; (I) healthy famciclovir-treated (30 mg/kg) cats; (J) URD-affected famciclovir-treated (90 mg/kg) cats; and (K) healthy famciclovir-treated (90 mg/kg) cats. (a) Species observed represents observed species richness, (b) Chao1 index represents estimated species richness, (c) inverse Simpson index represents diversity and (d) Shannon index represents species evenness. For each figure, boxes represent the range between the 25th and 75th percentiles, whiskers represent the 2.5th and 97.5th percentiles, the horizontal line inside the boxes defines the median, and closed circles represent outliers

abundance of *Proteobacteria* (which was decreased at day 8 vs day 1) and *Mycoplasma* (which increased from day 1 to day 8). By contrast, differences in the alpha diversity of the conjunctival microbiota during the same period were not detected. This suggests that changes within the conjunctival microbiota of individual cats were relatively minor, with assessment at the population or subpopulation level providing greater insight.

Differences in community membership and structure (beta diversity) between days 1 and 8 were also observed for multiple subpopulations of famciclovir-treated cats, including all cats treated with famciclovir (regardless of URD status or dose), and healthy or URD-affected cats receiving either dose of famciclovir. By contrast, the only subpopulation of untreated cats that experienced changes in both community structure and membership between

days 1 and 8 was the healthy untreated group. The similar changes noted in healthy untreated and all famciclovir-treated cats may suggest a direct or indirect beneficial effect of famciclovir on the conjunctival microbiota as has been noted in germ-free mice, where antiviral effects, independent of the microbiota, were observed following topical aminoglycoside administration.³⁴ Meanwhile, median relative abundance of *Mycoplasma* also increased in famciclovir-treated cats in the present study when considered as one group regardless of dose or URD status. However, this same change was also seen in URD-affected untreated, but not URD-affected placebo-treated, cats. There is no apparent clinical rationale for the difference between placebo-treated and untreated cats; sampling error cannot be definitively ruled out in this instance. Overall, it is unclear whether famciclovir

Figure 7 Alpha diversity of the conjunctival microbiota assessed using 75 swabs collected immediately after a 7-day study period initiated at shelter entry and in which cats were untreated or received orally administered famciclovir at 30 mg/kg or 90 mg/kg or placebo (lactose) q12h. Swabs were collected from 75 cats with ($n = 35$) or without ($n = 40$) clinical evidence of upper respiratory disease (URD). For data analysis, cats were considered within 11 populations as described in Figure 1: (A) entire population; (B) healthy untreated cats; (C) URD-affected untreated cats; (D) URD-affected placebo-treated cats; (E) healthy and URD-affected famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (F) healthy famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (G) URD-affected famciclovir-treated (30 mg/kg and 90 mg/kg) cats; (H) URD-affected famciclovir-treated (30 mg/kg) cats; (I) healthy famciclovir-treated (30 mg/kg) cats; (J) URD-affected famciclovir-treated (90 mg/kg) cats; and (K) healthy famciclovir-treated (90 mg/kg) cats. (a) Species observed represents observed species richness, (b) Chao1 index represents estimated species richness, (c) inverse Simpson index represents diversity and (d) Shannon index represents species evenness. For each figure, boxes represent the range between the 25th and 75th percentiles, whiskers represent the 2.5th and 97.5th percentiles, the horizontal line inside the boxes defines the median, and closed circles represent outliers

administration affected the median relative abundance of *Mycoplasma*, or if this was a reflection of the increase seen in the entire population, especially given that famciclovir-treated cats formed the second-largest subpopulation. However, concurrent changes in community structure and membership of the three largest famciclovir-treated subpopulations may provide some evidence that famciclovir was associated with this change. While our data suggest that a 1-week course of famciclovir affects the feline conjunctival microbiome, no difference due to famciclovir dose was detected. Previous work by our group in the same population of cats revealed that treatment with famciclovir had no significant impact on URD clinical disease scores.²⁸ It is possible that famciclovir has a minor impact on the beta diversity of the conjunctival microbiota but that this difference is too small to cause clinically distinguishable alterations in disease status.

It is reasonable to assume that cat handling or stress during famciclovir administration may also have affected the microbiome, as shelter-housed cats with higher stress scores were 5.6 times more likely to develop URD than those with lower stress scores.³⁵ However, our data do not support such a correlation. At neither day 1 nor 8 were there any differences in community membership or structure of URD-affected placebo-treated cats vs URD-affected untreated cats, suggesting that twice-daily handling for oral medication administration did not significantly alter the conjunctival microbiota.

The only subpopulations in which only community structure differed between days 1 and 8 were the URD-affected untreated and the URD-affected placebo-treated cats, while changes in only community membership were detected in healthy cats treated with 30 mg/kg or 90 mg/kg famciclovir. This raises the possibility that

Table 4 Community membership (Jaccard index) and structure (Yue and Clayton index) by analysis of molecular variance (AMOVA) and UniFrac from 124 conjunctival swabs collected from shelter-housed cats with (68 swabs) or without (56 swabs) clinical evidence of upper respiratory disease (URD) that were untreated or received orally administered famciclovir at one of two doses or placebo (lactose) q12h for 7 days

Beta diversity (community membership and structure) in healthy and URD-affected cats				
Subpopulations compared	Day	Analysis	Jaccard (membership) <i>P</i> value	Yue/Clayton (structure) <i>P</i> value
Healthy vs URD-affected, untreated	Day 1	AMOVA	0.900	0.772
		UniFrac	0.364	0.598
	Day 8	AMOVA	0.651	0.357
		UniFrac	0.428	0.264
Placebo vs untreated, URD-affected	Day 1	AMOVA	0.738	0.786
		UniFrac	0.714	0.737
	Day 8	AMOVA	0.271	0.132
		UniFrac	0.921	0.876
Healthy vs URD-affected, famciclovir-treated (30mg/kg)	Day 1	AMOVA	0.678	0.495
		UniFrac	0.853	0.482
	Day 8	AMOVA	0.263	0.737
		UniFrac	0.140	0.645
Healthy vs URD-affected, famciclovir-treated (90mg/kg)	Day 1	AMOVA	0.292	0.465
		UniFrac	0.258	0.274
	Day 8	AMOVA	0.506	0.527
		UniFrac	0.416	0.580

Swabs were collected prior to (day 1) and immediately after (day 8) the 7-day treatment period. Data are compared between healthy and URD-affected cats for clinically relevant subpopulations at each timepoint

Table 5 Community membership (Jaccard index) and structure (Yue and Clayton index) by analysis of molecular variance (AMOVA) and UniFrac from 69 conjunctival swabs collected from shelter-housed cats with (35 swabs) or without (34 swabs) clinical evidence of upper respiratory disease (URD) that were untreated or received orally administered famciclovir at one of two doses q12h for 7 days

Beta diversity (community membership and structure) in healthy and URD-affected cats treated with 30mg/kg vs 90mg/kg famciclovir at days 1 and 8				
Subpopulations compared	Day	Analysis	Jaccard (membership) <i>P</i> value	Yue/Clayton (structure) <i>P</i> value
Healthy, famciclovir-treated (30mg/kg vs 90mg/kg)	Day 1	AMOVA	0.797	0.469
		UniFrac	0.653	0.546
	Day 8	AMOVA	0.932	0.695
		UniFrac	0.921	0.684
URD-affected, famciclovir-treated (30mg/kg vs 90mg/kg)	Day 1	AMOVA	0.889	0.874
		UniFrac	0.469	0.257
	Day 8	AMOVA	0.285	0.848
		UniFrac	0.433	0.112

Swabs were collected prior to (day 1) and immediately after (day 8) the 7-day treatment period. Data are compared between famciclovir doses at each timepoint

famciclovir administration or health status are primarily responsible for these changes. Given that the two doses of famciclovir assessed in the present study did not differentially impact the microbiota, and because URD

status was the common factor for cats with altered community membership, it seems more likely that URD status may be responsible for this change. This is similar to data from a study in which the conjunctival microbiota

Table 6 Median relative abundance of *Mycoplasma* and Proteobacteria from 69 conjunctival swabs collected from healthy (34 swabs) or upper respiratory disease (URD)-affected (35 swabs) shelter-housed cats receiving 30 mg/kg or 90 mg/kg of orally administered famciclovir q12h for 7 days

Subpopulation assessed	Day	Median relative abundance (n = number of swabs)					
		<i>Mycoplasma</i>			Proteobacteria		
		30mg/kg	90mg/kg	P value	30mg/kg	90mg/kg	P value
URD-affected, famciclovir-treated cats	Day 1	0.0064 (8)	0.0146 (5)	0.622	0.1555 (8)	0.1428 (5)	0.943
	Day 8	0.0605 (13)	0.0215 (9)	0.423	0.1190 (13)	0.2124 (9)	0.205
Healthy, famciclovir-treated cats	Day 1	0.0029 (6)	0.0083 (10)	0.303	0.2034 (6)	0.2693 (8)	0.282
	Day 8	0.0214 (10)	0.0128 (13)	0.556	0.1242 (10)	0.1388 (10)	0.427

Swabs were collected prior to (day 1) and immediately after (day 8) the 7-day treatment period. No significant differences were detected for the remaining three ocular surface pathogens (*Chlamydiae*, *Streptococcus* and *Pseudomonas*)

of healthy cats receiving erythromycin for 7 days was stable overall.³⁶ In humans, altered relative abundance of microbial species, lower bacterial diversity and different ocular surface microbiota have been demonstrated in affected and fellow eyes of patients with fungal keratitis vs healthy eyes.³⁷ Similarly, human eyes with bacterial conjunctivitis had a higher overall bacterial count but fewer mean number of species cultured than did healthy eyes.³⁸ By contrast, in the present study a difference was not detected at day 1 or day 8 between the conjunctival microbiotas of healthy vs URD-affected untreated cats, or healthy compared with URD-affected cats treated with 30 mg/kg or 90 mg/kg famciclovir. Therefore, while differences in community structure of URD-affected cats and in community membership of healthy cats are detectable after 1 week in a shelter, these changes may not be large enough to reveal a significant difference between healthy and URD-affected cats. This suggests that the feline conjunctival microbiota was relatively conserved over the entire study population, with small and similar changes occurring in healthy and URD-affected cats. This is consistent with previous data from cats with or without conjunctivitis.²⁰

Limitations of this study include those inherent to all microbiota analyses, including uncertainty in determining cause-and-effect relationships due to the multivariate nature of host-microbiome interactions. 16S rRNA sequencing has limited ability to characterize sequences to lower taxons,¹¹ which restricted sequence characterization in the present study to the phylum or genus level. Investigation of feline ocular surface pathogens at the species level would have allowed more in-depth comparison of the conjunctival microbiota among subpopulations. Finally, the cats evaluated in the present study were from a shelter population, which may limit application of these data to client-owned cats maintained in smaller groups; however, shelter populations represent a clinically important group with respect to infectious disease and were selected for this reason. Though

environment, treatment and sample collection were standardized following shelter entry, prior history (medical and otherwise) is unknown, as is the effect these factors may have had on the conjunctival microbiota.

Conclusions

Our data reveal that beta diversity of the conjunctival microbiota changes after cats have been housed within a shelter for 1 week. The complexity and number of potential interactions among factors studied here do not permit determination of definitive causal relationships for this change. Although treatment with famciclovir appears to exert an impact on the feline conjunctival microbiota, the dose administered did not alter the beta diversity of the conjunctival microbiota of URD-affected or healthy cats. The absence of change in alpha diversity suggests that changes within the conjunctival microbiota of individual cats are minimal.

Acknowledgements We thank the Solano County Sheriff's Office Animal Care Division and Sheriff Thomas A Ferrara for use of their animal adoption facility; IDEXX Laboratories for performance of the qPCR; Monica Motta BS, RVT, RLAT, for technical support; Kate Hurley DVM, and Michael Bannasch BS, RVT, for assistance with project design; and the following undergraduate students for preparation of study medications and data collection: Christina Ball, Connor Chang, Marisa Ciccuzzi, Megan Coyne, Nadya Dooley, Alyssa Hoehn, Anny Huang, Winter Keith, Jessica Kwok, Jayden Li, Kira Lin, Kimberly Ly, Ariana Marangakis, Hannah Morris, Huong Nguyen, Josefina Nordenstahl, Allison O'Donnell, Sanskruti Potnis, Mengyue Wang and Isabel Warner.

Conflict of interest The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding This work was supported by grants from the Morris Animal Foundation and the UC Davis Centre for Companion Animal Health and RM Cello Endowment.

Ethical approval This work involved the use of non-experimental animals (owned or unowned) and procedures that differed from established internationally recognised high standards ('best practice') of veterinary clinical care for the individual patient. The study therefore had ethical approval from an established committee as stated in the manuscript.

Informed consent Informed consent (either verbal or written) was obtained from the owner or legal custodian of all animal(s) described in this work (either experimental or non-experimental animals) for the procedure(s) undertaken (either prospective or retrospective studies). No animals or humans are identifiable within this publication, and therefore additional informed consent for publication was not required.

ORCID iD Danica R Lucyshyn <https://orcid.org/0000-0001-7054-3869>
David J Maggs <https://orcid.org/0000-0001-6537-4335>
Ann E Cooper <https://orcid.org/0000-0001-6393-0406>

References

- Honneffer JB, Minamoto Y and Suchodolski JS. **Microbiota alterations in acute and chronic gastrointestinal inflammation of cats and dogs.** *World J Gastroenterol* 2014; 20: 16489–16497.
- Kugadas A and Gadjeva M. **Impact of microbiome on ocular health.** *Ocul Surf* 2016; 14: 342–349.
- Banks KC, Ericsson AC, Reinero CR, et al. **Veterinary ocular microbiome: lessons learned beyond the culture.** *Vet Ophthalmol* 2019; 22: 716–725.
- Turnbaugh PJ, Ley RE, Hamady M, et al. **The human microbiome project.** *Nature* 2007; 449: 804–810.
- Dorn ES, Tress B, Suchodolski JS, et al. **Bacterial microbiome in the nose of healthy cats and in cats with nasal disease.** *PLoS One* 2017; 12: e0180299. DOI: 10.1371/journal.pone.0180299.
- Willcox MD. **Characterization of the normal microbiota of the ocular surface.** *Exp Eye Res* 2013; 117: 99–105.
- Hooper LV, Littman DR and Macpherson AJ. **Interactions between the microbiota and the immune system.** *Science* 2012; 336: 1268–1273.
- Dong Q, Brulc JM, Iovieno A, et al. **Diversity of bacteria at healthy human conjunctiva.** *Invest Ophthalmology Vis Sci* 2011; 52: 5408–5413.
- Lu LJ and Liu J. **Human microbiota and ophthalmic disease.** *Yale J Biol Med* 2016; 89: 325–330.
- Flancman R, Singh A and Weese JS. **Evaluation of the impact of dental prophylaxis on the oral microbiota of dogs.** *PLoS One* 2018; 13: e0199676. DOI: 10.1371/journal.pone.0199676.
- Poussin C, Sierro N, Boue S, et al. **Interrogating the microbiome: experimental and computational considerations in support of study reproducibility.** *Drug Discov Today* 2018; 23: 1644–1657.
- Prehn-Kristensen A, Zimmermann A, Tittmann L, et al. **Reduced microbiome alpha diversity in young patients with ADHD.** *PLoS One* 2018; 13: e0200728. DOI: 10.1371/journal.pone.0200728.
- Lozupone C and Knight R. **UniFrac: a new phylogenetic method for comparing microbial communities.** *Appl Environ Microbiol* 2005; 71: 8228–8235.
- Schloss PD. **Evaluating different approaches that test whether microbial communities have the same structure.** *ISME J* 2008; 2: 265–275.
- Li S, Yi G, Peng H, et al. **How ocular surface microbiota debuts in type 2 diabetes mellitus.** *Front Cell Infect Microbiol* 2019; 9: 202. DOI: 10.3389/fcimb.2019.00202.
- Miller D and Iovieno A. **The role of microbial flora on the ocular surface.** *Curr Opin Allergy Clin Immunol* 2009; 9: 466–470.
- Ramachandran L, Sharma S, Sankaridurg PR, et al. **Examination of the conjunctival microbiota after 8 hours of eye closure.** *CLAO J* 1995; 21: 195–199.
- Callender MG, Tse LS, Charles AM, et al. **Bacterial flora of the eye and contact lens. Cases during hydrogel lens wear.** *Am J Optom Physiol Opt* 1986; 63: 177–180.
- Büttner JN, Schneider M, Csokai J, et al. **Microbiota of the conjunctival sac of 120 healthy cats.** *Vet Ophthalmol* 2019; 22: 328–336.
- Kielbowicz Z, Ploneczka-Janeczko K, Bania J, et al. **Characteristics of the bacterial flora in the conjunctival sac of cats from Poland.** *J Small Anim Pract* 2015; 56: 203–206.
- Espinola MB and Lilenbaum W. **Prevalence of bacteria in the conjunctival sac and on the eyelid margin of clinically normal cats.** *J Small Anim Pract* 1996; 37: 364–366.
- Weese JS, Nichols J, Jalali M, et al. **The rectal microbiota of cats infected with feline immunodeficiency virus infection and uninfected controls.** *Vet Microbiol* 2015; 180: 96–102.
- Suchodolski JS, Foster ML, Sohail MU, et al. **The fecal microbiome in cats with diarrhea.** *PLoS One* 2015; 10: e0127378. DOI: 10.1371/journal.pone.0127378.
- Bannasch MJ and Foley JE. **Epidemiologic evaluation of multiple respiratory pathogens in cats in animal shelters.** *J Feline Med Surg* 2005; 7: 109–119.
- Pedersen NC and Pratt PW. **Common infectious diseases of multiple-cat environments.** In: Pratt PW (ed). *Feline husbandry: diseases and management in the multiple-cat environment*. Goleta, CA: American Veterinary Publications, 1991, p 175.
- Pedersen NC, Sato R, Foley JE, et al. **Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus.** *J Feline Med Surg* 2004; 6: 83–88.
- Gourkow N, Lawson JH, Hamon SC, et al. **Descriptive epidemiology of upper respiratory disease and associated risk factors in cats in an animal shelter in coastal western Canada.** *Can Vet J* 2013; 54: 132–138.
- Cooper AE, Thomasy SM, Drazenovich TL, et al. **Prophylactic and therapeutic effects of twice-daily famciclovir administration on infectious upper respiratory disease in shelter-housed cats.** *J Feline Med Surg* 2019; 21: 544–552.
- Maggs DJ, Nasisse MP and Kass PH. **Efficacy of oral supplementation with L-lysine in cats latently infected with feline herpesvirus.** *Am J Vet Res* 2003; 64: 37–42.
- Caporaso JG, Lauber CL, Walters WA, et al. **Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample.** *Proc Natl Acad Sci U S A* 2011; 108 Suppl 1: 4516–4522.
- Walters W, Hyde ER, Berg-Lyons D, et al. **Improved bacterial 16S rRNA gene (V4 and V4-5) and fungal internal transcribed spacer marker gene primers for microbial**

- community surveys. *mSystems* 2016; 1: e00009–15. DOI: 10.1128/mSystems.00009-15.
- 32 Schloss PD, Westcott SL, Ryabin T, et al. **Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.** *Appl Environ Microbiol* 2009; 75: 7537–7541.
- 33 Wang Q, Garrity GM, Tiedje JM, et al. **Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy.** *Appl Environ Microbiol* 2007; 73: 5261–5267.
- 34 Gopinath S, Kim MV, Rakib T, et al. **Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner.** *Nat Microbiol* 2018; 3: 611–621.
- 35 Tanaka A, Wagner DC, Kass PH, et al. **Associations among weight loss, stress, and upper respiratory tract infection in shelter cats.** *J Am Vet Med Assoc* 2012; 240: 570–576.
- 36 Darden JE, Scott EM, Arnold C, et al. **Evaluation of the bacterial ocular surface microbiome in clinically normal cats before and after treatment with topical erythromycin.** *PLoS One* 2019; 14: e0223859. DOI: 10.1371/journal.pone.0223859.
- 37 Ge C, Wei C, Yang BX, et al. **Conjunctival microbiome changes associated with fungal keratitis: metagenomic analysis.** *Int J Ophthalmol* 2019; 12: 194–200.
- 38 Aoki R, Fukuda K, Ogawa M, et al. **Identification of causative pathogens in eyes with bacterial conjunctivitis by bacterial cell count and microbiota analysis.** *Ophthalmology* 2013; 120: 668–676.